Clear Cell Carcinoma Clinical Trials

11 recruitingLast updated: June 18, 2026

There are 11 actively recruiting clear cell carcinoma clinical trials across 17 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable. Top locations include Houston, Texas, United States, Ann Arbor, Michigan, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


Clear Cell Carcinoma Trials at a Glance

11 actively recruiting trials for clear cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Houston, Ann Arbor, and Atlanta. Lead sponsors running clear cell carcinoma studies include Tongji Hospital, M.D. Anderson Cancer Center, and Genelux Corporation.

Browse clear cell carcinoma trials by phase

Treatments under study

About Clear Cell Carcinoma Clinical Trials

Looking for clinical trials for Clear Cell Carcinoma? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Clear Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Clear Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 3

INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Ovarian Clear Cell Carcinoma
Tongji Hospital226 enrolled1 locationNCT07002346
Recruiting
Phase 2

CD70-targeted immunoPET Imaging of Malignant Cancers

LymphomaRenal CancerMantle Cell Lymphoma+4 more
RenJi Hospital300 enrolled1 locationNCT06852638
Recruiting
Phase 2

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

Ovarian NeoplasmsUterine Cervical NeoplasmsEndometrial Neoplasms+3 more
Yonsei University198 enrolled27 locationsNCT06023862
Recruiting
Phase 1

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

Phase 1Clear Cell CarcinomaGrowth Factor
M.D. Anderson Cancer Center30 enrolled1 locationNCT07072234
Recruiting
Phase 3

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer+4 more
Genelux Corporation186 enrolled31 locationsNCT05281471
Recruiting
Phase 2

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy

Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer+1 more
North Eastern German Society of Gynaecological Oncology640 enrolled47 locationsNCT05460000
Recruiting
Not Applicable

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

Urothelial CarcinomaMetastatic Urothelial CarcinomaRenal Cell Carcinoma+9 more
University of Texas Southwestern Medical Center600 enrolled1 locationNCT04623502
Recruiting
Phase 1Phase 2

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Ovarian Clear Cell Carcinoma
M.D. Anderson Cancer Center21 enrolled1 locationNCT06065462
Recruiting
Phase 1Phase 2

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776
Recruiting

A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary

Ovarian Clear Cell Carcinoma
Tongji Hospital150 enrolled1 locationNCT06279104
Recruiting
Phase 2

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

Renal Cell CarcinomaKidney CancerRenal Clear Cell Carcinoma
Fudan University66 enrolled1 locationNCT06211790